Decolonizing the gut from multidrug-resistant bacteria: Current strategies and future perspectives. [PDF]
Mishra A, Juneja D.
europepmc +1 more source
Tissue Engineered Human Elastic Cartilage From Primary Auricular Chondrocytes for Ear Reconstruction
Despite over three decades of research, no tissue‐engineered solution for auricular reconstruction in microtia patients has reached clinical translation. The key challenge lies in generating functional elastic cartilage ex vivo. Here, we integrate synergistic cell‐biomaterial strategies to engineer auricular grafts with mechanical and histological ...
Philipp Fisch +13 more
wiley +1 more source
Hybrid Electrospun Fibers for Rapid Delivery of <i>Lactobacillus paragasseri</i> K7 and Lactoferrin as Live Biotherapeutics and Postbiotics. [PDF]
Simonič M +4 more
europepmc +1 more source
Living Hydrogels: Harnessing Microorganism–Material Synergy for Next‐Generation Therapeutics
. ABSTRACT Microorganism‐based therapies, particularly those utilizing probiotics, have emerged as a powerful biomedical strategy owing to their inherent living functionalities. These living systems can dynamically interact with host environments and self‐regulate their activity, offering superior adaptability, prolonged functionality, and ...
Shuifang Mao +3 more
wiley +1 more source
Precision Microbial Therapeutics for Infertility: Next-Generation Probiotics, Engineered Biologics and Translational Pathways. [PDF]
Li L +9 more
europepmc +1 more source
Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models
Distal/connecting tubules expressing SLC8A1 have been suggested as a potential origin of ARPKD cysts. SPTAN1 has been identified as a key molecule in ARPKD cyst formation. Restoring SPTAN1 in PKHD1−/− organoids reduced cyst formation, normalized calcium levels, and decreased RAC1/c‐FOS expression, highlighting SPTAN1's role in ARPKD and the potential ...
Shohei Kuraoka +9 more
wiley +1 more source
A novel throughput assay to assess molecular hydrophobicity during early biotherapeutic developability assessments. [PDF]
Crames M, Davis M, Marlow MS.
europepmc +1 more source
Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg +10 more
wiley +1 more source
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett +20 more
wiley +1 more source
Probiotics and Phytoantioxidants as Emerging Neuroprotective Strategies: Bridging the Therapeutic Gap in Open Heart Surgery-Induced Brain Injury. [PDF]
Chu Y, Huang KH, Tseng CN.
europepmc +1 more source

